<DOC>
	<DOCNO>NCT00004886</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness MS 209 plus docetaxel treating patient advance solid tumor .</brief_summary>
	<brief_title>MS 209 Plus Docetaxel Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose oral MS-209 give docetaxel IV patient advance solid malignant tumor . - Assess toxicity regimen patient . OUTLINE : This dose escalation , multicenter study MS-209 . Patients receive docetaxel IV 1 hour day 1 3 week course . On day 1 2nd course , patient receive MS-209 orally follow docetaxel IV 1 hour . Treatment repeat every 3 week 4-7 course ( include course docetaxel alone ) . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos MS-209 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 3 6 patient experience dose limit toxicity . Patients follow every 6 week . PROJECTED ACCRUAL : Approximately 3-30 patient accrue study .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Dofequidar</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced malignant solid tumor No gastric cancer No brain involvement leptomeningeal disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 11.2 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.4 mg/dL Cardiovascular : Normal cardiac function Left ventricular ejection fraction normal Other : No digestive disease hamper absorption No unstable systemic disease uncontrolled infection precludes study No psychological , familial , sociological , geographical condition precludes compliance Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) No prior docetaxel No concurrent chemotherapy Endocrine therapy : At least 4 week since prior hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy ( 6 week extensive ) Surgery : Not specify Other : No concurrent anticancer drug No concurrent investigational therapy No H2blockers , proton pump inhibitor , sucralfate drug would impair absorption No concurrent drug exhibit liver , kidney , heart lung toxicity No concurrent MDRmodulating drug ( e.g. , calcium antagonist , immunosuppressive ) No concurrent antifungal ( ketoconazole , fluconazole ) antibiotic ( clarithromycin , erthromycin ) interfere MS209 metabolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>